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Glatiramer acetate treatment negatively
regulates type I interferon signaling
ABSTRACT
Objective: Glatiramer acetate (GA; Copaxone), a disease-modifying therapy for multiple sclerosis (MS),
promotes development of anti-inflammatory (M2, type II) monocytes that can direct differentiation of
regulatory T cells. We investigated the innate immune signaling pathways that participate in GA-
mediated M2 monocyte polarization.
Methods: Monocytes were isolated from myeloid differentiation primary response gene 88 (MyD88)–
deficient, Toll-IL-1 receptor domain–containing adaptor inducing interferon (IFN)–b (TRIF)–deficient, IFN-a/b
receptor subunit 1 (IFNAR1)–deficient, and wild-type (WT) mice and human peripheral blood. GA-treated
monocytes were stimulated with Toll-like receptor ligands, then evaluated for activation of kinases and
transcription factors involved in innate immunity, and secretion of proinflammatory cytokines. GA-treated
micewere evaluated for cytokine secretion and susceptibility to experimental autoimmune encephalomyelitis.
Results: GA-mediated inhibition of proinflammatory cytokine production by monocytes occurred inde-
pendently of MyD88 and nuclear factor–kB, but was blocked by TRIF deficiency. Furthermore, GA did
not provide clinical benefit in TRIF-deficient mice. GA inhibited activation of p38 mitogen-activated
protein kinase, an upstream regulator of activating transcription factor (ATF)–2, and c-Jun N-terminal
kinase 1, which regulates IFN regulatory factor 3 (IRF3). Consequently, nuclear translocation of ATF-2
and IRF3, components of the IFN-b enhanceosome, was impaired. Consistent with these observations,
GA inhibited production of IFN-b in vivo in WT mice, but did not modulate proinflammatory cytokine
production by monocytes from IFNAR1-deficient mice.
Conclusion: Our results demonstrate that GA inhibits the type I IFN pathway in M2 polarization of mono-
cytes independently of MyD88, providing an important mechanism connecting innate and adaptive immune
modulation in GA therapy and valuable insight regarding its potential use with other MS treatments. Neurol
Neuroimmunol Neuroinflamm 2015;2:e179; doi: 10.1212/NXI.0000000000000179
GLOSSARY
APC 5 antigen-presenting cells; BMDM 5 bone marrow–derived monocytes; cAMPi 5 intracellular cyclic adenosine
39,59-monophosphate; EAE 5 experimental autoimmune encephalomyelitis; GA 5 glatiramer acetate; IFN 5 interferon;
IFNAR 5 type I interferon receptor; IFNAR1 5 interferon-a/b receptor subunit-1; IL 5 interleukin; IRF3 5 interferon regu-
latory factor 3; JNK1 5 c-Jun N-terminal kinase 1; LPS 5 lipopolysaccharide; LTA 5 lipoteichoic acid; MHC 5 major histo-
compatibility complex; MS 5 multiple sclerosis; MyD88 5 myeloid differentiation primary response gene 88; NF 5 nuclear
factor; PBS 5 phosphate-buffered saline; PI3K 5 phosphoinositide 3-kinase; STAT 5 signal transducers and activators of
transcription; Th 5 T helper; TLR 5 Toll-like receptor; TNF 5 tumor necrosis factor; Treg 5 regulatory T cells; TRIF 5 Toll-IL-1
receptor domain–containing adaptor inducing interferon-b;WT 5 wild-type.
Glatiramer acetate (GA; copolymer-1, Copaxone), a random basic copolymer, is prescribed for
treatment of relapsing-remitting multiple sclerosis (MS). Previously, it was demonstrated that
GA therapy induces anti-inflammatory M2 (type II) myeloid cells.1–3 GA-induced M2 mono-
cytes reversed ongoing paralysis in experimental autoimmune encephalomyelitis (EAE) and, as
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antigen-presenting cells (APC), promoted
expansion of regulatory T cells (Treg) and T
helper (Th) 2 cells.3 Thus, induction of M2
APC is a proximal event responsible for T-cell
regulation associated with GA therapy.
While the molecular mechanisms required
for GA-mediated M2 differentiation and ther-
apeutic efficacy of GA have not been fully elu-
cidated, it is recognized that GA inhibits
monocyte reactivity in response to engage-
ment of Toll-like receptors (TLRs),1,3 suggest-
ing that modulation of innate signaling could
represent a principal mechanism of action of
GA. In general, TLR engagement triggers acti-
vation through interaction with adaptor mol-
ecule myeloid differentiation primary response
gene 88 (MyD88) or Toll-IL-1 receptor
domain–containing adaptor inducing inter-
feron (IFN)–b (TRIF). Both pathways
are important in CNS autoimmunity.4–6
MyD88-dependent signaling is associated
with activation of the nuclear factor (NF)–kB
pathway and is required for Th17 differen-
tiation in EAE.7 In contrast, signaling via
TRIF leads to activation of IFN regulatory
factor 3 (IRF3) transcription factor and subse-
quent production of IFN-b.8 Signaling
through TRIF, IRF3, or the type I IFN recep-
tor (IFNAR) also influences development of
Th17 cells and EAE.5,6,9 Thus, reduction of
proinflammatory cytokines observed following
stimulation of M2 monocytes could indicate
that GA modulates MyD88, TRIF, or both
pathways.
The goal of this investigation was to identify
the molecular pathways participating in differ-
entiation of M2 APC by GA. Our results,
which demonstrate that GA downregulates
type I IFN signaling, provide a key mechanism
responsible for inhibition of proinflammatory
APC polarization by GA treatment.
METHODS Mice. Female 8- to 10-week-old C57BL/6 wild-
type (WT), IFN-a/b receptor subunit-1 (IFNAR1)–deficient,
TRIF-deficient, and CD11b-deficient mice were obtained from
Jackson Laboratories (Bar Harbor, ME). C57BL/6 MyD88-
deficient mice were provided by Dr. A. DeFranco (University
of California, San Francisco). Mice were maintained and
handled in accordance with UCSF Institutional Animal Care
and Use Committee regulations for the humane use of animals
in research.
EAE induction. C57BL/6J mice were injected SC with 50 mg
MOG p35-55 (Auspep, Parkville, Australia) emulsified in
complete Freund’s adjuvant containing 200 mg heat-killed
Mycobacterium tuberculosis on day 0. Mice received 200 ng
Bordetella pertussis toxin (List Biological Laboratories,
Campbell, CA) IV in 0.2 mL phosphate-buffered saline (PBS)
on days 0 and 2. Mice were observed daily. Mice received one SC
injection of a 0.1-mL emulsion consisting of 250 mg GA
(provided by Teva Pharmaceutical Industries, Petah Tikva,
Israel) in an equal volume of PBS and incomplete Freund’s
adjuvant in the upper flanks on the same day of immunization
(day 0). Clinical scores were assessed as follows: 0 5 no clinical
disease, 1 5 loss of tail tone only, 2 5 mild monoparesis or
paraparesis, 3 5 severe paraparesis, 4 5 paraplegia or
quadriparesis, and 5 5 moribund or death.
Monocyte isolation and culture. CD11b1CD11c2 macro-
phages (purity .98%) were obtained from C57BL/6 WT,
MyD88-deficient, IFNAR1-deficient, TRIF-deficient, and
CD11b-deficient mice. Bone marrow–derived monocytes
(BMDM) were obtained following in vitro GA or vehicle (PBS)
treatment, for 7 days in RPMI, 10% FCS, and 10% L929
cell-conditioned medium (L929-CM), which was used as a
source of murine M-CSF. Mouse BMDM and peripheral
macrophages stained positively for CD11b, F4/80, and major
histocompatibility complex (MHC) class II (I-A) cell surface
molecules. For cyclic adenosine 39,59-monophosphate (cAMP)
quantification, DNA binding, and ELISA assays, monocytes
were cultured in 96-well plates at 2.5 3 104 cells/well in 200
mL culture media. For Western blot analyses, monocytes
differentiated in the presence or absence of GA were
resuspended at 10 3 106 cells/mL in culture media, and 2 mL
were plated in 6-well plates at 37°C for 1 hour, then activated
with indicated stimuli. Human peripheral blood buffy coat
monocytes were isolated from healthy volunteers as previously
described.10 Human monocytes expressed cell surface CD14,
MHC class II (HLA-DR), and CD68 molecules. Monocytes
were cultured in 96-well plates at 5 3 104 cells/well in 200 mL
media, and activated with the indicated stimuli for 24 hours.
Monocytes were stimulated with forskolin (an agonist of
adenylyl cyclase and serves as a positive control for induction
of intracellular cAMP), lipopolysaccharide (LPS), Poly(I:C),
lipoteichoic acid (LTA), and Pam3CSK4, which were
purchased from InvivoGen (San Diego, CA).
ELISA. Production of tumor necrosis factor (TNF), interleukin
(IL)–6, and IFN-b was measured in serum or culture superna-
tants by ELISA (eBioscience, San Diego, CA; R&D Systems,
Minneapolis, MN), per manufacturer protocol. Intracellular
cAMP (cAMPi) was detected using Biotrack kit (GE Healthcare,
Cleveland, OH).
DNA binding. DNA binding of ATF-2 and IRF3 was
quantitated from monocyte nuclear extracts using the ELISA-
based Transfactor (Clontech, Mountain View, CA) and
TransAM (Active Motif, Carlsbad, CA) kits, respectively.
Western blot. Total cell lysates were prepared frommonocyte cul-
tures and subjected toWestern blot analysis as described previously.3
Nitrocellulose membranes were probed (4°C, overnight) with anti-
bodies against phospho-Akt1 (Ser473), phospho-JNK (Thr183/
Tyr185), phospho-p38 MAP kinase (Thr180/Tyr182), phospho-
IkBa (Ser32/36), glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), total STAT1, and total Akt1/2/3 (Cell Signaling
Technology, Danvers, MA). Horseradish peroxidase–conjugated
goat anti-mouse (Thermo Scientific, Waltham, MA) or sheep
anti-rabbit (Covalab, Villeurbanne, France) antibodies were used
for secondary detection. Antibody-bound proteins were detected
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by the Uptilight HRP Blot Chemiluminescent substrate (GE
Healthcare). Western blots were digitized and quantified using
NIH imageJ software (version 1.44).
Mouse phospho-Akt (Ser473) cell-based ELISA. PathScan
Phospho-Akt1 (Ser473) Sandwich ELISA Kit (Cell Signaling
Technology) was used to detect endogenous phospho-Akt1
(Ser473) protein. Equal concentrations of protein extract (100
mg/mL) were analyzed for each sample. The magnitude of
absorbance (450 nm) was proportional to the quantity of
phospho-Akt1 (Ser473) protein. Values were expressed as a
fraction of the amount of phospho-Akt1 (Ser473) observed in
BMDM extract, which was normalized to 1.
Statistics. Data are presented as the mean 6 SD. For ELISA
data, n 5 3 separate samples for each condition were examined.
When required, statistical significance of differences between
groups was evaluated using Student paired t test. Differences were
considered significant at a value of p , 0.05. For clinical scores,
significance between groups was examined using the Mann-
Whitney U test. A value of p , 0.05 was considered significant.
RESULTS GA induces activation of PI3K, but not
cAMP. Whether GA selectively engages specific recep-
tors is unclear. cAMP and phosphoinositide 3-kinase
(PI3K) are second messenger systems that can be
activated after receptor engagement, and have been
associated with early signaling events in anti-
inflammatory responses.11 As shown in figure 1A,
incubation of monocytes with GA did not induce
intracellular cAMP levels, as compared to stimulation
by the positive control, adenylylcyclase activator
forskolin, suggesting that GA-induced M2 differenti-
ation does not involve cAMP. Phosphorylation of Akt
on serine 473 is a surrogate marker of PI3K activa-
tion. Within 15 minutes, GA induced phosphoryla-
tion of Akt as measured both by Western blot
(figure 1B) and ELISA (figure 1C). These results sug-
gest that GA activates at least one intracellular second
messenger signaling pathway associated with reduc-
tion of inflammation in innate immune cells.
GA inhibits TRIF-dependent, but not MyD88-dependent,
signaling. MyD88 and TRIF represent the 2 essential
adapters of innate immune signaling. Previous data
demonstrated that GA treatment was associated with
reduction of proinflammatory cytokine production
and STAT1 phosphorylation in monocytes following
stimulation with LPS, a TLR4 agonist.3 All TLRs
utilize MyD88 except TLR3, which depends exclu-
sively on TRIF.8 TLR4 signals via both MyD88 and
TRIF. Therefore, it was possible that GA could inter-
fere withMyD88 or TRIF.We employed distinct TLR
agonists in order to distinguish between these 2 possi-
bilities. First, we observed that GA itself did not
alter baseline or ligand-induced expression of TLR2,
TLR3, or TLR4 (figure e-1 at Neurology.org/nn),
indicating that GA did not influence the capacity to
sense TLR agonists. As shown in figure 2A and
figure e-2, activation of GA-treated monocytes by the
Figure 1 Glatiramer acetate induces time-
dependent phosphorylation of Akt in
monocytes
(A) Monocytes were stimulated for 30 or 60 minutes with
50 mg/mL glatiramer acetate (GA) or forskolin (FK), a lab-
dane diterpene, which is an agonist of the enzyme aden-
ylyl cyclase, and serves as a positive control for induction
of intracellular cyclic adenosine 39,59-monophosphate
(cAMPi). Monocytes were lysed and cAMPi was deter-
mined by enzyme immunoassay. Values are expressed
as the mean 6 SD (n 5 3). Data are representative of 3
independent experiments. (B, C) Monocytes were stimu-
lated with 50 mg/mL GA for the indicated time periods
prior to cell lysis. (B) Cell lysates were then subjected to
sodium dodecyl sulfate polyacrylamide gel electrophore-
sis and immunoblotted with phospho-specific antibodies
to serine-473 of Akt1 (phospho-Akt1 [Ser473]). The same
blot was stripped and probed for total Akt. Relative ratio
represents the fold induction of Akt1 (Ser473) phospho-
rylation by GA treatment. (C) Endogenous levels of phos-
pho-Akt1 (Ser473) protein were detected by a solid phase
sandwich ELISA. The magnitude of absorbance is propor-
tional to the quantity of phospho-Akt1 (Ser473) protein.
*p , 0.05, **p , 0.01, ***p , 0.001 as determined by
Student t test. Results shown are representative of 2
separate experiments.
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TLR2 ligands, Pam3CSK4 or LTA, did not alter
TNF and IL-6 secretion. In contrast, secretion of
these proinflammatory cytokines was reduced when
GA-treated monocytes were activated by the TLR3
ligand, Poly(I:C), or the TLR4 ligand, LPS. These
results therefore suggested that GA inhibited TRIF-
dependent signaling and was independent of
MyD88. Similar to monocytes from WT mice,
monocytes from MyD88-deficient mice exhibited
reduced IL-6 and TNF levels following GA
treatment (figure 2A). Engagement of MyD88
activates NF-kB. As shown in figure 2B, GA
exposure did not impair phosphorylation and
degradation of the inhibitor protein IkBa following
LPS treatment. GA exposure also did not significantly
alter DNA binding of p50 or p65 NF-kB subunits
Figure 2 Glatiramer acetate treatment induced M2 differentiation through a MyD88-independent pathway
(A) As described previously,3 M2 monocytes were treated in the presence or absence of glatiramer acetate (GA) for 6 days.
They were then stimulated with lipopolysaccharide (LPS), Poly(I:C), or Pam3CSK4 for 24 hours. (B) Wild-type (WT) mono-
cytes cultured in the presence or absence of GA were stimulated with LPS (100 ng/mL) for the indicated duration. Cell
lysate proteins were separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis and membranes were probed
for phosphorylated IkBa (Ser32/36). Data are representative of 2 separate experiments. (C) Human peripheral blood mono-
cytes were preincubated for 1 hour with or without 50 mg/mL GA and then cultured for 24 hours in the presence or absence
of Poly(I:C) (10 mg/mL) or Pam3CSK4 (100 ng/mL). Tumor necrosis factor (TNF) (left panels) and interleukin (IL)–6 (right
panels) secretion was quantitated in cell supernatants by ELISA. Results are presented as mean 6 SD (n 5 3); **p , 0.01,
***p , 0.001 by Student t test. Data presented are representative of 3 independent experiments. MyD88 5 myeloid
differentiation primary response gene 88; TRIF 5 Toll-IL-1 receptor domain–containing adaptor inducing interferon-b.
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(data not shown). These results suggest that the NF-kB
pathway is dispensable for the immunologic effects of
GA on monocytes. Further, GA did not reduce
proinflammatory cytokine secretion in TRIF-deficient
monocytes (figure 2A), providing further support that
inhibition of TRIF-dependent signaling is required for
GA-mediated reduction of proinflammatory cytokine
secretion. As GA treatment of murine monocytes
suppressed proinflammatory cytokine production by
Poly(I:C), but not Pam3CSK4, we tested how GA-
treated human monocytes responded to these 2 TLR
ligands. GA treatment of human peripheral blood
monocytes decreased TNF and IL-6 secretion induced
by Poly(I:C), but not Pam3CSK4 (figure 2C). Thus, as
with murine monocytes, these results indicate that GA
inhibits proinflammatory cytokine production by
human monocytes by blocking TRIF-mediated
signaling.
The in vivo contribution of TRIF-dependent sig-
naling in modulating proinflammatory cytokine
secretion was also examined during GA treatment.
GA-treated WT mice that were stimulated with
LPS (figure 3A), but not with Pam3CSK4 (figure
3B), exhibited a significant reduction of serum
TNF and IL-6 levels. However, this modulation of
TNF and IL-6 was not observed in GA-treated TRIF-
deficient mice following LPS injection (figure 3B).
As MyD88-deficient mice are unresponsive to
Pam3CSK4 or LPS,12 these mice were evaluated by
stimulation with Poly(I:C). GA treatment reduced
proinflammatory cytokine serum levels in MyD88-
deficient mice in response to Poly(I:C) (figure 3C).
Thus, these in vivo results further establish that
GA inhibits TRIF-dependent, but not MyD88-
dependent, signaling.
We then addressed whether TRIF deficiency might
alter the clinical effect of GA treatment in EAE. TRIF-
deficient, but not MyD88-deficient, mice are suscepti-
ble to EAE.5–7 Clinical severity of EAE in untreated
WT and TRIF-deficient mice was similar (figure 3D).
However, GA suppressed EAE development in WT
mice but not in TRIF-deficient mice. Specifically,
the incidence, day of onset, and EAE severity were
not altered by GA treatment of TRIF-deficient mice.
These in vivo results further confirmed the importance
of modulating TRIF-dependent signaling in the clini-
cal activity of GA.
GA treatment inhibits IFN-b production by targeting
regulatory elements of the IFN-b promoter. IFN-b is a
key cytokine induced via the TRIF-dependent pathway
that contributes to both innate and adaptive immune
responses.4–6 Therefore, we analyzed expression of
IFN-b in monocytes treated with GA. As anticipated,
we observed a reduction of IFN-b secretion by
GA-treated WT monocytes (figure 4A). Serum IFN-b
was also decreased in GA-treated mice that were
subsequently challenged with LPS (figure 4B).
Through binding to IFNAR and activating the
signal transducers and activators of transcription
(STAT) signaling pathway, IFN-b acts in a feedback
manner to amplify monocyte responses to innate
stimulation.13 Previously, we reported that STAT1
phosphorylation was impaired in M2 monocytes.3
Thus, we addressed the importance of IFNAR1 in
GA treatment. As shown in figure 4C, IFNAR1 defi-
ciency prevented GA-mediated modulation of IL-6
and TNF secretion. Together, these results suggest
that reduction of type I IFN signaling may be a pri-
mary effect of GA action on monocytes.
Type I IFN expression requires the coordinated
activation of the transcription factors NF-kB, IRF3,
and ATF-2/c-Jun (AP-1), which comprise the IFN-b
enhanceosome.14 We evaluated the influence of GA
treatment on activation of these signaling molecules
and their regulators. As described above, GA treat-
ment did not influence NF-kB activation. In con-
trast, we observed that GA suppressed nuclear
translocation of IRF3 in monocytes following stimu-
lation with either LPS or Poly(I:C) (figure 4D). Acti-
vation and nuclear translocation of IRF3 are
dependent upon phosphorylation by c-Jun N-terminal
kinase 1 (JNK1).15 In this regard, phosphorylation
of JNK1 was reduced in GA-treated monocytes in
response to LPS stimulation (figure 4E). Similarly,
decreased DNA binding of ATF-2 was observed fol-
lowing incubation with GA (figure 4F and figure e-3),
which corresponded to inhibition of p38 MAPK
phosphorylation (figure 4G), the major upstream reg-
ulator of ATF-2.16 Taken together, these results dem-
onstrate that GA treatment inhibited IFN-b
production by interfering with activation of transcrip-
tion factors participating in formation of the IFN-b
enhanceosome.
DISCUSSION Cellular immune responses that result
from GA treatment of MS and EAE have been well-
described.17,18 In 2007, it was shown that it is the
influence of GA on APCs that is responsible for the
amplification of Th2 and Treg cells, a study that pro-
vided the first demonstration that M2 monocytes could
reverse CNS autoimmune disease and promote T-cell
immune modulation in vivo.3 At that time the long-
held belief that GA-specific T cells required cross-
reactivity with myelin self-antigen for therapeutic
benefit was disproved. It was also observed that GA
treatment was associated with inhibition of STAT1 in
monocytes, indicating that GA affected at least one
proinflammatory signaling pathway within these cells.3
TRIF and MyD88 represent 2 major innate pathways
involved in the induction of several proinflammatory
responses, including cytokine secretion. Our results
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demonstrate that GA inhibits the TRIF-dependent path-
way, resulting in a reduction in activity of downstream
signaling molecules that lead to production of IFN-b
(figure 5). This immune modulation occurred indepen-
dently of MyD88 and did not influence NF-kB activa-
tion. These findings provide a key anti-inflammatory
mechanism connecting innate and adaptive immune
modulation in GA therapy.
Engagement of some cell surface receptors has
been associated with anti-inflammatory polarization
of myeloid cells. Vasoactive intestinal peptide, which,
similar to GA, also exerts anti-inflammatory effects,19
Figure 3 TRIF deficiency abrogates the immunomodulatory effects of glatiramer acetate treatment on
cytokines and experimental autoimmune encephalomyelitis
Wild-type (WT) and Toll-IL-1 receptor domain–containing adaptor inducing interferon-b (TRIF)–deficient mice treated with
glatiramer acetate (GA) or vehicle (n 5 5 mice/group) were injected IP with (A) lipopolysaccharide (LPS) (100 ng/kg) or (B)
Pam3CSK4 (100 ng/kg). (C) Myeloid differentiation primary response gene 88 (MyD88)–deficient mice were injected IP with
Poly(I:C) (10 mg/kg). Serum levels of tumor necrosis factor (TNF) and interleukin (IL)–6 were quantitated by ELISA 5 hours
after injection. Results are presented as the mean 6 SEM (n 5 3) of 2 experiments that provided similar results; *p, 0.05,
**p , 0.01, ***p , 0.001 as determined by Student t test. (D) On day 0, C57BL/6J WT (left) or TRIF-deficient mice (right)
mice were immunized with MOG peptide (p35-55; 50 mg). GA (250 mg) was administered once (SC in incomplete Freund’s
adjuvant [IFA]) on the same day as immunization (day 0). Control mice received a single SC injection of IFA. For all exper-
imental autoimmune encephalomyelitis experiments, mean disease score 6SEM is shown. *p , 0.05 as determined by
Mann-Whitney U test. Results shown are representative of 3 independent experiments.
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Figure 4 Glatiramer acetate treatment negatively regulates IFN-b production by targeting components of the
IFN-b enhanceosome
(A) Wild-type (WT) monocytes differentiated in the presence or absence of glatiramer acetate (GA) were stimulated with lip-
opolysaccharide (LPS) (100 ng/mL) for 24 hours. Interferon (IFN)–b secretion was quantitated in cell culture supernatants
by ELISA. Results are representative of 2 experiments. Data are presented as mean 6 SEM; *p , 0.05, **p , 0.01 as
determined by Student t test. (B) WT mice (n 5 3/group) treated with GA or vehicle were injected IP with LPS (100 ng/kg).
Serum levels of IFN-b were quantitated by ELISA, 5 hours following injection. Data are representative of 2 separate
experiments. (C) Interferon-a/b receptor subunit-1 (IFNAR1)–deficient monocytes differentiated in the presence or absence
of GA were stimulated with LPS at the indicated dose for 24 hours. Tumor necrosis factor (TNF) and interleukin-6 secretion
was quantitated in cell supernatants by ELISA. Results are representative of 3 independent experiments (n 5 3/group). (D)
Monocytes generated in the presence or absence of GA were stimulated with LPS (100 ng/mL) or Poly(I:C) (10 mg/mL) for
the indicated duration. IRF3 binding activity in nuclear extracts wasmeasured with TransAM IRF3. (E) Monocytes generated
in the presence or absence of GAwere stimulated with LPS (100 ng/mL) for the indicated duration. Cell lysate proteins were
separated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and membranes were probed for
phosphorylated SAPK/JNK (Thr183/Tyr185) and total GAPDH. Data are representative of 3 separate experiments. (F) Mono-
cytes differentiated in the presence or absence of GA and stimulated with 100 ng/mL LPS for the indicated duration. DNA
binding of ATF-2 was quantitated from nuclear extracts. (G) Monocytes generated in the presence or absence of GA were
stimulated with LPS (100 ng/mL) for the indicated duration, and whole-cell lysates were subjected to SDS-PAGE and
Western blot analysis for phosphorylated p38 MAPK (Thr180/Tyr182) and total STAT1. Data are representative of 3 sep-
arate experiments.
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triggers the second messengers PI3K and cAMP fol-
lowing receptor engagement.20 We established that
PI3K, but not cAMP, participates in M2 polarization
by GA, and like a previous study of human mono-
cytes,21 further supports a central role for PI3K/Akt in
regulating inflammatory responses. These results also
suggest that GA, or its peptide degradation products,
might engage protein receptors. GA exhibits promis-
cuous binding to allelic surface MHC class II mole-
cules.22 Although the cytoplasmic domain of MHC
class II molecules can participate in intracellular
signaling, MHC class II is neither required for
GA-dependent anti-inflammatory monocyte func-
tions3 nor necessary for targeting of GA to these cells
in vivo. As data have indicated that GA can bind to
CD11b (CD18),23,24 a cell surface aMb2 integrin that
participates in immune regulation, it was speculated
that the interaction of GA with CD11b might
contribute to GA-mediated modulation. However,
we have observed that during in vivo GA treatment,
GA or its byproducts accumulate equally well in
CD11b-deficient monocytes as CD11b-bearing
(WT) monocytes and that CD11b expression is not
required for GA-mediated M2 differentiation (figure
e-4). These findings highlight the challenges in iden-
tifying a specific receptor that binds GA and leads to
activation of second messengers. Indeed, GA, a ran-
dom linear arrangement of glutamate, lysine, alanine,
and tyrosine (i.e., glat in glatiramer) that exhibits
extensive sequence variation, may interact with many
macromolecules.
Other random basic synthetic copolymers have
also been considered for development as potential
therapies in MS.25 In this regard, one random copol-
ymer containing phenylalanine, lysine, alanine, and
tyrosine and another composed of valine, lysine,
Figure 5 TLR-dependent signaling pathways inhibited by glatiramer acetate
Myeloid differentiation primary response gene 88 (MyD88) and Toll-IL-1 receptor domain–containing adaptor inducing
interferon-b (TRIF) are 2 major mediators of Toll-like receptor (TLR) signaling that cooperate in promoting innate immune
responses. Engagement of TLR2 by Pam3CSK4 or lipoteichoic acid (LTA) initiates the MyD88-dependent pathway
resulting in the transcription of proinflammatory cytokines via the induction (black lines) of nuclear factor (NF)–kB.
Stimulation of TLR3 by Poly(I:C) induces the recruitment of TRIF, which in turn triggers expression of interferon (IFN)–b
by activating interferon regulatory factor 3 (IRF3), a substrate of c-Jun N-terminal kinase 1 (JNK1).15 Engagement of
TLR4 by lipopolysaccharide (LPS) triggers both MyD88-dependent and TRIF-dependent signaling. Both TLR3 and TLR4,
but not TLR2, initiate an IFN-b-positive feedback loop that amplifies the initial response through the IFNAR–signal
transducers and activators of transcription 1 (STAT1) signaling axis. The differentiation of M2 monocytes occurred
independently of MyD88 and phosphorylation and degradation of the NF-kB inhibitor, IkBa. In contrast, TRIF-dependent
TLR signaling was negatively regulated in M2 monocytes. Phosphorylation of JNK1 and p38 MAPK and subsequent
nuclear translocation (DNA binding) of IRF3 and ATF-2, 2 components of the IFN-b enhanceosome, were inhibited. GA-
mediated M2monocyte differentiation is associated with inhibition of STAT1 phosphorylation.3 Copyright Xavier Studio,
reprinted with permission.
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alanine, and tryptophan also prevent EAE and cause
immune modulation.25,26 Further, lysine—the basic
amino acid common to these copolymers—is essen-
tial for therapeutic benefit, as “gat”-iramer acetate,
lacking lysine, was ineffective in preclinical EAE stud-
ies. Thus, the observation that other synthetic ran-
dom basic copolymers that, like GA, contain alanine,
lysine, and an aromatic amino acid (i.e., phenylala-
nine, tryptophan, or tyrosine) also induce immune
modulation raises the possibility that the signaling
pathways modulated by GA identified in this report
may be common to this class of copolymers.
While the observation that GA exerts anti-
inflammatory activity via inhibition of TRIF and its
downstream signaling molecules is novel, it is known
that the glucocorticoid dexamethasone also promotes
M2 polarization.27 Although some data indicate that
steroids interfere with NF-kB-dependent signaling,
other results have demonstrated that steroid-mediated
M2 polarization is primarily associated with inhibition
of both IRF3 activation and type I IFN signaling.28
Resveratrol, an antioxidant found in red wine, inhibits
TRIF-dependent activation,29 and, like GA, reduces
clinical EAE and macrophage-mediated inflammatory
activity.30 Thus, while the mechanism of action of GA
is unique among MS therapeutics, suppression of
TRIF-dependent signal transduction by agents that
exhibit anti-inflammatory activity is not unprecedented.
Our finding that GA prevents IFN-b synthesis in
M2 monocytes is consistent with the earlier demon-
stration that STAT1 phosphorylation is reduced
upon activation in these cells.3 One may find these
observations surprising, considering that IFN-b is
approved for treatment of MS and has been protective
in some EAE models.5,6 However, GA and IFN-b
promote immune modulation via distinct mecha-
nisms. For example, GA and IFN-b not only exhibit
opposing activities on STAT1 phosphorylation, an
obligate initial step in IFN-b signaling,31 but also
demonstrate distinct effects on proinflammatory
T-cell differentiation. Whereas GA induces both
Th2 and Treg cells that can modulate Th1 and
Th17 responses,3,18 respectively, some data indicate
that IFN-b downregulates pathogenic Th1, but not
Th17 responses.32 Separately, it was observed that
deficiency in either IRF3 or JNK1 reduced suscepti-
bility to EAE and impaired expansion of Th17
cells.9,33 Thus, our findings that GA treatment in-
hibited activation of JNK1 and nuclear translocation
of IRF3 in monocytes and reduced production of
IFN-b are consistent both with the knowledge that
inhibition of TRIF-dependent gene products reduces
Th17 differentiation and that GA inhibits Th17
polarization.3 Together with the observation that
GA prevented nuclear translocation of ATF-2, which
contributes to the activation of the IFN-b promoter,
our data indicate that GA inhibits formation of the
IFN-b enhanceosome, a complex that is required for
maximal IFN-b gene transcription.
Considerable effort has been devoted to the iden-
tification of therapeutics that may provide additive or
synergistic benefit when combined for treatment of
MS.34–37 Even though mixed results were obtained
when GA was tested in combination with type I IFNs
in preclinical studies,38,39 GA and intramuscular IFN-
b-1a were tested separately and together in a phase III
clinical trial in relapsing-remitting MS.35 GA alone
reduced relapse rate more than IFN-b-1a, and was
equivalent to the combination of GA and IFN-b.
While tempting to translate our mechanistic findings
in relation to those clinical results, one should exercise
caution; our study has focused primarily on identifi-
cation of the mechanisms employed by GA in M2
monocyte polarization. Further, while results of that
phase III MS trial did not identify clinical benefit
from the combination of GA and intramuscular
IFN-b-1a, it did not provide clear evidence of antag-
onism either. Evidence of synergy or antagonism may
be dependent upon dosing. For example, when
cholesterol-lowering statins were administered in
combination with low-dose (intramuscular) or high-
dose (subcutaneous) IFN-b in MS clinical trials,
antagonism was observed and appeared more evident
with high-dose IFN-b40,41; this effect may relate to
the opposing actions of these medications on STAT1
activation.36 In retrospect, our observation here that
GA treatment inhibited expression of IFN-b in
monocytes would not have provided mechanistic sup-
port for testing the combination of GA and IFN-b in
MS. Recognizing that GA regulates TRIF-dependent
IFN-b production in monocytes may provide insight
regarding its therapeutic effects in MS and for iden-
tification of surrogate markers of its efficacy.
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